Stock TOVX THERIVA BIOLOGICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Theriva Biologics, Inc.

Equities

TOVX

US87164U4094

Market Closed - Nyse
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
0.2501 USD -6.43% Intraday chart for Theriva Biologics, Inc. -18.27% -41.85%
May. 23 Theriva Biologics Gets Fast Track Designation for Pancreatic Cancer Treatment MT
May. 23 Theriva Biologics, Inc Announces U.S. Food and Drug Administration Granted Fast Track Designation CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Theriva Biologics Gets Fast Track Designation for Pancreatic Cancer Treatment
MT
Theriva Biologics, Inc Announces U.S. Food and Drug Administration Granted Fast Track Designation
CI
Theriva™ Biologics Announces Fast Track Designation Granted by the U.S. FDA for VCN-01 for the Treatment of Metastatic Pancreatic Cancer
AQ
Theriva™ Biologics to Participate in the A.G.P. Virtual Healthcare Conference
AQ
Theriva Biologics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Theriva™ Biologics Reports First Quarter 2024 Operational Highlights and Financial Results
AQ
Theriva™ Biologics to Discuss the Trial Design for VIRAGE - a Phase 2b Clinical Study of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma - at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
AQ
Theriva™ Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory Retinoblastoma
AQ
Theriva Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory Retinoblastoma
CI
Theriva™ Biologics to Present Preclinical Data Supporting the Potential Synergy of VCN-01 and First-Line Pancreatic Cancer Chemotherapy Regimens at the American Society for Cell and Gene Therapy 27th Annual Meeting
AQ
Theriva™ Biologics Announces Presentation at the American Society for Cell and Gene Therapy 27th Annual Meeting
AQ
Transcript : Theriva Biologics, Inc., 2023 Earnings Call, Mar 25, 2024
Theriva™ Biologics Reports Full-Year 2023 Operational Highlights and Financial Results
AQ
Theriva Biologics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
North American Morning Briefing : Tech in Focus on -2-
DJ
Theriva™ Biologics to Host Conference Call and Webcast to Discuss Full Year 2023 Operational Highlights and Financial Results
AQ
Theriva™ Biologics to Participate in the BIO-Europe Spring Conference
AQ
Theriva Biologics Announces Positive Recommendation from the Independent Data Monitoring Committee of VIRAGE, the Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma
AQ
Theriva Biologics Announces Positive Recommendation from the Independent Data Monitoring Committee of VIRAGE, the Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma
CI
Theriva Biologics to Participate in the B. Riley Securities Annual Oncology Conference
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TOVX Stock
  4. News Theriva Biologics, Inc.